Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the ...
Researchers have used a drug screening platform they developed to show that an antidepressant, currently on the market, kills tumor cells in the dreaded glioblastoma -- at least in the cell-culture ...